Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Authors
Keywords
-
Journal
HYPERTENSION RESEARCH
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-16
DOI
10.1038/s41440-020-00585-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
- (2019) Hiroshi Itoh et al. HYPERTENSION RESEARCH
- Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?
- (2019) Atsuhisa Sato HYPERTENSION RESEARCH
- Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
- (2019) Hiromi Rakugi et al. HYPERTENSION RESEARCH
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
- (2018) Lei Li et al. HYPERTENSION RESEARCH
- Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016
- (2016) Murray Epstein et al. AMERICAN JOURNAL OF MEDICINE
- Third-generation Mineralocorticoid Receptor Antagonists
- (2016) Elise P. Gomez-Sanchez JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Blood Pressure, Proteinuria, and Renal Function Decline: Associations in a Large Community-Based Population
- (2015) Atsushi Hirayama et al. AMERICAN JOURNAL OF HYPERTENSION
- Rate of Change in Renal Function and Mortality in Elderly Treated Hypertensive Patients
- (2015) E. K. Chowdhury et al. Clinical Journal of the American Society of Nephrology
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
- (2015) Mitja Lainscak et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Pharmacological treatment of aldosterone excess
- (2015) Jaap Deinum et al. PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis
- (2014) Francesco Pelliccia et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study
- (2013) Kazuaki Shimamoto et al. HYPERTENSION RESEARCH
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Mineralocorticoid receptor antagonists: their use and differentiation in Japan
- (2012) Atsuhisa Sato HYPERTENSION RESEARCH
- Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension
- (2012) GianLuca Colussi et al. JOURNAL OF HYPERTENSION
- Mineralocorticoid Receptor Antagonist for Renal Protection
- (2012) Terry King-Wing Ma et al. RENAL FAILURE
- The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease
- (2011) Nicola C. Edwards et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease
- (2011) R Pisoni et al. JOURNAL OF HUMAN HYPERTENSION
- Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy
- (2010) Jodi Heshka et al. Journal of the American Society of Hypertension
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started